Point72 Asia Singapore Pte. Ltd. Grows Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Point72 Asia Singapore Pte. Ltd. boosted its holdings in AstraZeneca PLC (NASDAQ:AZN) by 122.4% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 1,728 shares of the company’s stock after buying an additional 951 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in AstraZeneca were worth $135,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. GHP Investment Advisors Inc. bought a new stake in AstraZeneca during the 2nd quarter valued at approximately $26,000. Able Wealth Management LLC bought a new stake in shares of AstraZeneca during the fourth quarter valued at approximately $27,000. Pathway Financial Advisers LLC purchased a new position in shares of AstraZeneca in the first quarter worth $29,000. Pin Oak Investment Advisors Inc. boosted its position in shares of AstraZeneca by 468.4% during the fourth quarter. Pin Oak Investment Advisors Inc. now owns 449 shares of the company’s stock worth $30,000 after acquiring an additional 370 shares during the last quarter. Finally, RFP Financial Group LLC grew its stake in AstraZeneca by 56.3% during the first quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock valued at $33,000 after acquiring an additional 178 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on AZN. Citigroup upgraded AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. TD Cowen lifted their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Finally, Barclays upgraded shares of AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Trading Down 0.7 %

Shares of AZN opened at $77.62 on Friday. The company’s fifty day simple moving average is $81.68 and its 200-day simple moving average is $76.97. The company has a market cap of $240.66 billion, a P/E ratio of 38.05, a P/E/G ratio of 1.45 and a beta of 0.47. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.01. The business had revenue of $12.45 billion during the quarter, compared to the consensus estimate of $12.62 billion. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.08 earnings per share. As a group, analysts expect that AstraZeneca PLC will post 4.05 EPS for the current year.

AstraZeneca Cuts Dividend

The firm also recently disclosed a Semi-Annual dividend, which was paid on Monday, September 9th. Shareholders of record on Friday, August 9th were given a $0.49 dividend. This represents a yield of 1.8%. The ex-dividend date was Friday, August 9th. AstraZeneca’s dividend payout ratio (DPR) is presently 48.04%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.